TCM
REGN icon

Traynor Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Traynor Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Sell
3,005
-28,461
-90% -$19.4M 0.09% 97
2026
Q1 		$23.6M Buy
31,466
+103
+0.3% +$78.9K 1.38% 12
2025
Q4 		$24.2M Buy
31,363
+755
+2% +$513K 1.29% 13
2025
Q3 		$17.2M Buy
30,608
+1,129
+4% +$638K 0.98% 19
2025
Q2 		$15.8M Buy
29,479
+1,623
+6% +$906K 1.12% 19
2025
Q1 		$17.7M Buy
27,856
+3,066
+12% +$2.11M 1.49% 11
2024
Q4 		$17.7M Buy
24,790
+2,400
+11% +$2.01M 1.18% 15
2024
Q3 		$23.5M Buy
22,390
+2,071
+10% +$2.3M 1.41% 14
2024
Q2 		$21.4M Buy
20,319
+573
+3% +$555K 1.6% 12
2024
Q1 		$19M Buy
19,746
+878
+5% +$835K 1.65% 11
2023
Q4 		$16.6M Buy
18,868
+667
+4% +$549K 1.7% 10
2023
Q3 		$15M Buy
18,201
+684
+4% +$538K 1.88% 8
2023
Q2 		$12.6M Buy
17,517
+610
+4% +$470K 1.54% 11
2023
Q1 		$13.9M Buy
16,907
+1,153
+7% +$870K 2.01% 9
2022
Q4 		$11.4M Sell
15,754
-2,409
-13% -$1.78M 1.6% 10
2022
Q3 		$12.5M Buy
18,163
+176
+1% +$111K 2.23% 8
2022
Q2 		$10.6M Buy
17,987
+43
+0.2% +$28K 1.84% 10
2022
Q1 		$12.5M Buy
17,944
+671
+4% +$425K 1.63% 11
2021
Q4 		$10.9M Buy
17,273
+2,287
+15% +$1.41M 1.29% 17
2021
Q3 		$9.07M Buy
14,986
+1,396
+10% +$867K 1.24% 17
2021
Q2 		$7.93M Buy
13,590
+947
+7% +$480K 1.11% 21
2021
Q1 		$5.98M Buy
12,643
+482
+4% +$235K 0.99% 24
2020
Q4 		$5.88M Buy
12,161
+1,949
+19% +$1.05M 1.04% 23
2020
Q3 		$5.92M Buy
10,212
+685
+7% +$415K 1.36% 13
2020
Q2 		$5.94M Buy
9,527
+3,320
+53% +$1.88M 1.43% 13
2020
Q1 		$3.03M Buy
6,207
+3,273
+112% +$1.35M 1.08% 21
2019
Q4 		$1.1M Sell
2,934
-14
-0.5% -$4.71K 0.29% 72
2019
Q3 		$817K Sell
2,948
-103
-3% -$30.5K 0.26% 73
2019
Q2 		$966K Buy
3,051
+62
+2% +$20.6K 0.31% 65
2019
Q1 		$1.23M Buy
2,989
+1,376
+85% +$567K 0.41% 49
2018
Q4 		$602K Buy
1,613
+9
+0.6% +$3.29K 0.25% 68
2018
Q3 		$648K Sell
1,604
-27
-2% -$10.3K 0.21% 74
2018
Q2 		$572K Buy
1,631
+145
+10% +$45.3K 0.21% 76
2018
Q1 		$511K Sell
1,486
-46
-3% -$16K 0.21% 77
2017
Q4 		$575K Buy
1,532
+12
+0.8% +$4.86K 0.25% 79
2017
Q3 		$661K Sell
1,520
-120
-7% -$57.1K 0.31% 67
2017
Q2 		$833K Sell
1,640
-30
-2% -$13.1K 0.41% 54
2017
Q1 		$671K Sell
1,670
-65
-4% -$24.1K 0.37% 58
2016
Q4 		$597K Sell
1,735
-450
-21% -$171K 0.4% 54
2016
Q3 		$804K Sell
2,185
-105
-5% -$42.1K 0.57% 39
2016
Q2 		$823K Sell
2,290
-245
-10% -$94.4K 0.64% 38
2016
Q1 		$913K Sell
2,535
-310
-11% -$128K 0.73% 31
2015
Q4 		$1.54M Buy
2,845
+125
+5% +$67.7K 1.11% 23
2015
Q3 		$1.26M Buy
2,720
+25
+0.9% +$13.4K 1.09% 22
2015
Q2 		$1.37M Buy
2,695
+70
+3% +$34.2K 1.15% 17
2015
Q1 		$1.19M Buy
2,625
+285
+12% +$121K 1.14% 18
2014
Q4 		$959K Buy
+2,340
New +$920K 1.12% 16

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

Traynor Capital Management's REGN Position: Q2 2026 in Review

Traynor Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 90% in Q2 2026, selling an estimated $19.4M and leaving 3,005 shares worth $1.87M. The position accounts for 0.09% of the portfolio, ranked #97.

Traynor Capital Management first reported a position in REGN in Q4 2014 and has held it in 47 quarters since. The position peaked at $24.2M in Q4 2025. 307 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Traynor Capital Management held 3,005 shares of Regeneron Pharmaceuticals worth $1.87M as of Q2 2026.
  • Traynor Capital Management sold 28,461 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $19.4M.
  • Regeneron Pharmaceuticals made up 0.09% of Traynor Capital Management's portfolio in Q2 2026, its #97 holding.
  • Traynor Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • Traynor Capital Management's Regeneron Pharmaceuticals position peaked at $24.2M in Q4 2025.
  • 307 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Traynor Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.